Raloxifene

Grey

Brand Name(s):Evista

Indication:Primary prevention of osteoporotic fractures in postmenopausal women

Rationale:1

Considered:Oct-07

Review Date:Jan-26

Comments:
NICE TA160: Raloxifene is not recommended as a treatment option for the primary prevention of osteoporotic fragility fractures in postmenopausal women.